Hypoxia as a Biomarker and for Personalized Radiation Oncology.
Recent Results Cancer Res. 2016;198:123-142
Authors: Vordermark D, Horsman MR
Abstract
Tumor hypoxia is a clinically relevant cause of radiation resistance. Direct measurements of tumor oxygenation have been performed predominantly with the Eppendorf histograph and these have defined the reduced prognosis after radiotherapy in poorly oxygenated tumors, especially head-and-neck cancer, cervix cancer and sarcoma. Exogenous markers have been used for immunohistochemical detection of hypoxic tumor areas (pimonidazole) or for positron-emission tomography (PET) imaging (misonidazole). Overexpression of hypoxia-related proteins such as hypoxia-inducible factor-1α (HIF-1α) has also been linked to poor prognosis after radiotherapy and such proteins are considered as potential endogenous hypoxia markers.
PMID: 27318684 [PubMed - as supplied by publisher]
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/28IyJud
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου